July 27, 2023
The Third Circuit on Thursday backed a finding that generic-drug maker Mylan was not on the hook for $50 million in taxes the Internal Revenue Service said it should pay over deducted patent litigation fees.
January 12, 2023
A Third Circuit panel questioned the government's position that generic-drug maker Mylan owes $50 million in taxes, asking during oral arguments Thursday why the IRS had suddenly changed its mind in claiming the company shouldn't be allowed to deduct its litigation costs.
January 04, 2023
Collegiate athletes' fight for pay leads the Third Circuit's argument calendar this month, along with cases tackling the tax deductibility of litigation expenses and whether the "gist of action" doctrine applies in a case against Dick's Sporting Goods.
September 20, 2022
A recent Court of Federal Claims decision supports Mylan Inc.'s challenge to a $50 million tax bill by bolstering its argument that it's entitled to deduct the costs of patent litigation suits, Mylan told the Third Circuit.
August 09, 2022
A generic-drug manufacturer trade group told the Third Circuit on Monday that taxing patent litigation costs related to the expedited approval process for generic drugs would undermine the purpose of the Hatch-Waxman Act that set up that process, driving up costs for consumers.
August 02, 2022
Generic-drug maker Mylan urged the Third Circuit to uphold a decision that the company was not on the hook for $50 million in taxes the Internal Revenue Service said it should pay over deducted patent litigation fees.
May 19, 2022
Pharmaceutical company Mylan Inc. should be held liable for more than $50 million in taxes, the U.S. told the Third Circuit, arguing a lower court incorrectly concluded the business could claim certain patent litigation costs as standard business deductions.